Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Juan Ramón Ayuso
Based on 6 articles published since 2009
(Why 6 articles?)
||||

Between 2009 and 2019, Juan R. Ayuso wrote the following 6 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Guideline [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. 2016

Martin-Richard, Marta / Ginès, Angels / Ayuso, Juan Ramón / Sabater, Luis / Fabregat, Joan / Mendez, Ramiro / Fernández-Esparrach, Glòria / Molero, Xavier / Vaquero, Eva C / Cuatrecasas, Miriam / Ferrández, Antonio / Maurel, Joan / Anonymous3560884. ·Servicio de Oncología Médica, Hospital Sant Pau, Barcelona, España. Electronic address: mmartinri@santpau.cat. · Servicio de Gastroenterología, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Radiología, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Cirugía, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Cirugía, Hospital de Bellvitge, Barcelona, España. · Servicio de Radiología, Hospital Clínico San Carlos, Madrid, España. · Servicio de Gastroenterología, Hospital Vall d'Hebron, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínic de Barcelona, Barcelona, España. · Servicio de Anatomía Patológica, Hospital Clínico Universitario de Valencia, Valencia, España. · Servicio de Oncología Médica, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, España. ·Med Clin (Barc) · Pubmed #27726847.

ABSTRACT: BACKGROUND AND OBJECTIVE: Clinical management of adenocarcinoma of the pancreas is complex, and requires a multidisciplinary approach. The same applies for the premalignant lesions that are increasingly being diagnosed. The current document is an update on the diagnosis and management of premalignant lesions and adenocarcinoma of the pancreas. PATIENTS AND METHODS: A conference to establish the basis of the literature review and manuscript redaction was organized by the Grupo Español Multidisciplinar en Cáncer Digestivo. Experts in the field from different specialties (Gastroenterology, Surgery, Radiology, Pathology, Medical Oncology and Radiation Oncology) met to prepare the present document. RESULTS: The current literature was reviewed and discussed, with subsequent deliberation on the evidence. CONCLUSIONS: Final recommendations were established in view of all the above.

2 Clinical Trial Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). 2018

Maurel, Joan / Sánchez-Cabús, Santiago / Laquente, Berta / Gaba, Lydia / Visa, Laura / Fabregat, Joan / Povés, Ignacio / Roselló, Susana / Díaz-Beveridge, Roberto / Martín-Richard, Marta / Rodriguez, Javier / Sabater, Luis / Conill, Carles / Cambray, María / Reig, Ana / Ayuso, Juan Ramón / Valls, Carlos / Ferrández, Antonio / Bombí, Josep Antoni / Ginés, Angels / García-Albéniz, Xabier / Fernández-Cruz, Laureano. ·Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. jmaurel@clinic.cat. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Medical Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. · Department of Oncology, Hospital Mar, Barcelona, Spain. · Surgical Department, Hospital Bellvitge, Hospitalet, Spain. · Surgical Department, Hospital del Mar, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Valencia, Valencia, Spain. · Medical Oncology Department, Hospital La Fe, Valencia, Spain. · Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain. · Medical Oncology Department, Hospital Clínico Universitario Navarra, Pamplona, Spain. · Surgical Department, Hospital Clínico Valencia, Valencia, Spain. · Radiotherapy Oncology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiotherapy Oncology Department, Institut Català d'Oncologia, Hospitalet, Spain. · Radiotherapy Oncology Department, Hospital Mar, Barcelona, Spain. · Radiology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Radiology Department, Hospital Bellvitge, Hospitalet, Spain. · Pathology Department, Hospital Clínico Valencia, Valencia, Spain. · Pathology Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Gastrointestinal Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. · Harvard T.H. Chan School of Public Health, Boston, MA, USA. · Surgical Department, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. lfcruz@clinic.cat. ·Cancer Chemother Pharmacol · Pubmed #30225601.

ABSTRACT: BACKGROUND: Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients. METHODS: Patients with confirmed resectable PDAC after agreement by two expert radiologists were eligible. Patients received three cycles of GEM (1000 mg/m RESULTS: Twenty-five patients were enrolled. Adverse effects of NAT were mainly mild gastrointestinal disorders. Resectability rate was 76%, with a R0 rate of 63.1% among the resected patients. Median overall survival (OS) and disease-free survival (DFS) were 23.8 (95% CI 11.4-36.2) and 12.8 months (95% CI 8.6-17.1), respectively. R0 resection patients had better median OS, compared with patients with R1 resection or not resected (65.5 months vs. 15.5 months, p = 0.01). N0 rate among the resected patients was 63.1%, and showed a longer median OS (65.5 vs. 15.2 months, p = 0.009). CONCLUSION: The results of this study confirm promising oncologic results with NAT for patients with resectable PDAC. Therefore, the present trial supports the development of phase II randomized trials comparing NAT vs. upfront surgery in resectable pancreatic cancer.

3 Clinical Trial A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. 2014

Aparicio, Jorge / García-Mora, Carmen / Martín, Marta / Petriz, Ma Lourdes / Feliu, Jaime / Sánchez-Santos, Ma Elena / Ayuso, Juan Ramón / Fuster, David / Conill, Carlos / Maurel, Joan. ·Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. · Department of Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. · Department of Medical Oncology, Hospital de Sant Pau, Barcelona, Spain. · Department of Radiation Oncology, Hospital de Sant Pau, Barcelona, Spain. · Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. · Department of Radiation Oncology, Hospital Universitario La Paz, Madrid, Spain. · Department of Radiology, Hospital Clínic, Barcelona, Spain. · Department of Nuclear Medicine, Hospital Clínic, Barcelona, Spain. · Department of Radiation Oncology, Hospital Clínic, Barcelona, Spain. · Department of Medical Oncology, Hospital Clínic, Barcelona, Spain. ·PLoS One · Pubmed #24416138.

ABSTRACT: PURPOSE: Sorafenib, an oral inhibitor of B-raf, VEGFR2, and PDGFR2-beta, acts against pancreatic cancer in preclinical models. Due to the radio-sensitization activity of both sorafenib and gemcitabine, we designed a multicenter, phase I trial to evaluate the safety profile and the recommended dose of this combination used with concomitant radiation therapy. METHODS: Patients with biopsy-proven, unresectable pancreatic adenocarcinoma (based on vascular invasion detected by computed tomography) were treated with gemcitabine (300 mg/m2 i.v. weekly ×5 weeks) concurrently with radiation therapy (45 Gy in 25 fractions) and sorafenib (escalated doses in a 3+3 design, from 200 to 800 mg/day). Radiation portals included the primary tumor but not the regional lymph nodes. Patients with planning target volumes (PTV) over 500 cc were excluded. Cases not progressing during chemoradiation were allowed to continue with sorafenib until disease progression. RESULTS: Twelve patients were included. Three patients received 200 mg/day, 6 received 400 mg/day, and 3 received 800 mg/day; PTVs ranged from 105 to 500 cc. No dose-limiting toxicities occurred. The most common grade 2 toxicities were fatigue, neutropenia, nausea, and raised serum transaminases. Treatment was discontinued in one patient because of a reversible posterior leukoencephalopathy. There were no treatment-related deaths. CONCLUSION: The addition of sorafenib to concurrent gemcitabine and radiation therapy showed a favorable safety profile in unresectable pancreatic adenocarcinoma. A dose of 800 mg/day is recommended for phase II evaluation. TRIAL REGISTRATION: EudraCT 2007-003211-31 ClinicalTrials.gov 00789763.

4 Article [Pseudopapillary solid tumor of the pancreas: report of 6 cases]. 2012

Navarro, Salvador / Ferrer, Joana / Bombí, Josep Antoni / López-Boado, Miguel Angel / Ayuso, Juan Ramón / Ginés, Angels / Fernández-Esparrach, Gloria / Vaquero, Eva / Cuatrecasas, Miriam / Fernández-Cruz, Laureano. ·Servicio de Gastroenterología, Hospital Clínic, Universidad de Barcelona, IDIBAPS, CIBERehd, Barcelona, España. snavarro@clinic.ub.es ·Med Clin (Barc) · Pubmed #22036462.

ABSTRACT: BACKGROUND AND OBJECTIVES: Solid pseudopapillary neoplasms (SPNs) are rare tumours of the exocrine pancreas. Although they can develop metastasis, the prognosis is good. The aim of this study was to describe the characteristics of these tumours attended in our hospital. PATIENTS AND METHOD: All cases of SPN in the database of the Pathology Department between 1991 and 2010 were included. Age, sex, symptoms, type of surgery, pathologic and immunohistochemical characteristics, and clinical evolution were analyzed. RESULTS: Six cases were identified; all of them were women with a median age of 27.5 years. One patient presented haemoperitoneum, 2 abdominal pain and 3 were diagnosed incidentally. The most frequent localization was the pancreatic tail (n=4) and the median size was 7.7 cm. Four tumours were benign and 2 carcinomas. One of them had liver and lymph node metastases. Ki-67 proliferation index was low (1-3%). After a median follow-up of 33.5 months, all patients were alive and without evidence of relapse. CONCLUSION: SPNs occur in young women. In most cases surgical resection is curative. A low mitotic index confers a good prognosis and a long survival.

5 Article [Malignancy predictive factors in pancreatic intraductal papillary mucinous neoplasm]. 2011

Adet Caldelari, Ana Celia / Miquel, Rosa / Bombi, Josep Antoni / Ginés, Angels / Fernández-Esparrach, Gloria / Ayuso, Juan Ramón / Maurel, Joan / Feu, Faust / Castells, Antoni / Fernández-Cruz, Laureano / Navarro, Salvador. ·Servicio de Gastroenterología, Institut de Malalties Digestives i Metabòliques, IDIBAPS, CIBERehd, Barcelona, Spain. ·Med Clin (Barc) · Pubmed #21414642.

ABSTRACT: BACKGROUND AND OBJECTIVE: Intraductal papillary mucinous neoplasm (IPMN) is a premalignant lesion of the pancreas. Its natural history is not well known. We evaluated the characteristics and predictor factors of malignancy of IPMN. PATIENTS AND METHOD: A retrospective analysis was performed in 88 patients diagnosed with IPMN between January 1997 and December 2008. The diagnosis was done by abdominal computed tomography (CT), pancreatic-magnetic resonance imaging (MRI) and/or endoscopic ultrasound (EUS). Gender, age, symptoms, origin, location, CA 19.9 serum levels, size of tumours and nodules by imaging techniques, type of surgery, malignancy and survival were evaluated. Nine pre-surgical variables were selected, and univariate and multivariate analysis to identify independent prognostic factors of malignancy were performed. RESULTS: The mean age was 64 years and 53% were men. 39% of tumours were incidental. 50% had their origin on the main pancreatic duct, 37% on collateral branchs and 13% were multifocal. 68% patients were operated: 42% had malignant neoplasms (32% carcinoma in situ and 68% invasive). Twelve patients died (1 benign, 1 in situ and 10 invasive). Univariate and multivariate analysis identified the symptoms and the tumour size (≥ 22 mm [median of our serie] and ≥ 30 mm [size accepted in literature]) as independent predictor factors of malignancy. CONCLUSIONS: Many IPMN are incidental findings. The presence of symptoms and size of the tumour are independent prognostic factors of malignancy and they should be considered to decide therapeutic actions.

6 Article [Incidence and characteristics of pancreatic cystic neoplasms]. 2010

Adet, Ana / Miquel, Rosa / Bombi, Josep A / Gines, Angels / Fernández-Esparrach, Gloria / De Juan, Carmen / Ayuso, Juan R / Maurel, Joan / Castells, Antoni / Fernández-Cruz, Laureano / Navarro, Salvador. ·Servicio de Gastroenterología, IDIBAPS, CIBERehd, Institut Malalties Digestives i Metabòliques, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, España. ·Gastroenterol Hepatol · Pubmed #20850905.

ABSTRACT: INTRODUCTION: Cystic neoplasms (CN) of the pancreas represent 10% of cystic lesions and 1% of pancreatic tumors. Mucinous cystic neoplasm (MCN), serous cystadenoma (SC) and intraductal papillary mucinous neoplasm (IPMN) are cystic neoplasms and represent more than 90% of these types of lesion. Few series have been published on these lesions, especially in Spain. AIM: To evaluate the incidence, characteristics and survival of patients with cystic neoplasms attended in our hospital in the last 12 years. PATIENTS AND METHOD: A retrospective analysis was carried out in all patients diagnosed with CN between January 1997 and December 2008. Diagnosis was made by abdominal computed tomography, pancreatic-magnetic resonance imaging and/or endoscopic ultrasonography. Sex, age, year of diagnosis, symptoms, tumoral location and size, type of surgery, pathology, and survival were evaluated. RESULTS: A total of 117 patients were analyzed. The mean age was 63±14 years and 56% were women. Eighty-eight patients had IPMN, 21 had SC and eight had MCN. Fifty-six per cent were diagnosed in the last 4 years, 42.7% were diagnosed as an incidental finding and 19% had a history of acute pancreatitis. The most frequent location was the pancreatic head (53%). The mean imaging size was 32mm. Surgical resection was performed in 69.2% of the patients. Twenty-three percent of the tumors were malignant, 30% were carcinoma in situ and 70% were invasive. Thirteen percent of the patients died; of these 93.3% had invasive carcinoma. Five-year survival was 94.7% in SC, 76% in IPMN and 60% in MCN. CONCLUSIONS: CN were mainly identified as incidental findings, although acute pancreatitis is another possible cause. The most frequent tumor in our environment is IPMN. Surgical treatment of IPMN and MCN, at the right moment, may be useful to prevent the development of pancreatic carcinoma.